

Precirix enters into alliance with 3P Biopharmaceuticals for the manufacturing of single domain antibodies

Brussels, Belgium and Noáin, Spain, 17 August 2021 – Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and 3P Biopharmaceuticals S.L.U. (3P), a leading CDMO based in Spain specializing in process development and GMP manufacturing of biological products, have signed an agreement for the clinical manufacturing of a camelid single domain antibody fragment (sdAb), the backbone of Precirix' next product candidate to enter the clinic.

As Precirix' lead compound, CAM-H2, is being evaluated in a Phase I/II clinical trial, the company is advancing its second product candidate towards the clinic. Large-scale manufacturing of the sdAb backbone is an important first step in this process. 3P Biopharmaceuticals will complete the technology transfer, process upscaling and manufacturing of the sdAb.

"This collaboration marks an important step in advancing our second pipeline program towards the clinic. We are confident 3P is the right partner for the manufacturing of our highly selective single domain antibody", said Ruth Devenyns, Chief Executive Officer of Precirix.

Dámaso Molero, Chief Executive Officer of 3P Biopharmaceuticals commented: *"The alliance with Precirix is an exciting new venture for 3P, where, once again, innovation and technology come together making it possible to develop novel drugs against cancer. We look forward to being part of the Precirix journey."*

About Precirix NV

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix' technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment. www.precirix.com

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a market-leading CDMO (Contract Development and Manufacturing Organization) specializing in process development and GMP (Good Manufacturing Practice) manufacturing of biologics and cell therapy products. 3P offers solutions for all manufacturing stages

PRECIRIX®



PRESS RELEASE

17 August 2021

related to new drug development including cell line and process development, analytical methods development, pre-clinical and clinical supply and commercial manufacturing.

In its 15-year history, 3P has produced around 60 molecules for more than 50 customers in some 20 countries. More information: <http://www.3pbio.com/>

For further information, please contact:

Precirix NV

Ruth Devenyns, CEO Precirix

+32 2 479 93 60

info@precirix.com

www.precirix.com

3P Biopharmaceuticals

Natalia Horstmann, Communications & PR Consultant

T +34 608 440091

comunicacion.consultor@3pbio.com